



BC PharmaCare Newsletter

July 10, 2013 Edition 13-005

Published by the Pharmaceutical Services Division to provide information for British Columbia’s health care providers

QuickLinks

Exchange Rate for Prosthetic Purchases Outside Canada	1
Veterinary Prescriptions—Important Reminder	1
Benefits.....	2
Re-listing of Low Cost Alternative (LCA) Categories.....	2

EXCHANGE RATE FOR PROSTHETIC PURCHASES OUTSIDE CANADA

United States (U.S.) exchange rates are reviewed regularly and adjusted as needed, based on the posted close-of-business rate published by the Bank of Canada.

Rates are adjusted whenever the rate changes by more than five cents and remains at a variance of five cents or more for at least five working days.

New U.S. Exchange Rate \$1.0372*

*Based on the [Bank of Canada](#) rate at the close of business on May 22, 2013.

VETERINARY PRESCRIPTIONS—IMPORTANT REMINDER

When dispensing veterinary medications, NEVER assign a PHN to an animal. Instead, use the PHN of the pet’s owner. To prevent the drug from adjudicating on PharmaNet and to ensure the drug will not appear on the pet owner’s patient record:

- Use the veterinarian’s license number as the Practitioner Identification (Pract. ID)
- Use **V9** as the Reference Code

Following the above requirements also ensures that the veterinary prescription will not affect Drug Utilization Evaluation (DUE) results for the pet’s owner.

The use of PharmaNet is not intended as a substitute for professional judgment.
Information on PharmaNet is not exhaustive and cannot be relied upon as complete.

The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.

BENEFITS

Re-listing of Low Cost Alternative (LCA) Categories

As announced in the [PharmaCare Newsletter 13-002](#) on February 28, 2013, PharmaCare has reviewed LCA categories for which no generic product met the maximum accepted list price (MALP). Effective April 1, 2013, coverage of some of these categories was removed as a lower strength product could be used (e.g., two or more tablets/capsules) in place of the higher strength product.

However, it has since come to our attention that a lower strength alternative is no longer available for one of the removed LCA categories; therefore the following LCA category has been reinstated. The products listed below are now eligible benefits.

DIN	DRUG NAME
VALPROIC ACID CAP EC 500MG	
2218321	Novo-Valproic - ECC 500 mg capsule
2229628	PMS- Valproic acid E.C. 500 mg capsule

Regular Benefits

The following new product is now an eligible PharmaCare benefit for Fair PharmaCare and Plans B, C, F, and, if indicated below, Plan G and/or Plan P.

DIN	DRUG NAME	PLAN G	PLAN P
2399466	5-aminosalicylic acid (Pentasa®) 1 gram extended-release tablet	N	N

Non-Benefits

The following products have been reviewed and will not be added as benefits under PharmaCare.

DIN	DRUG NAME
2373955	colesevelam (Lodalis™) 625 mg tablet
2361809	exenatide (Byetta™) multi-dose syringe pen delivering 5 µg per dose
2361817	exenatide (Byetta™) multi-dose syringe pen delivering 10 µg per dose
2379910	fampridine (Fampyra™) 10 mg sustained-release tablet